回复:想帮助这里所有的人--一个四十岁妻子受害人
AiCuris has completed a double-blind randomised placebo controlled dose-finding Phase-II trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection and is planning have first data in early 2011.
AiCuris said that the trial has been completed two months earlier than planned.
Indeed, in the later stages of the trial, enrollment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.
AiCuris Clinical Development associate director Burkhard Timmler said that they were surprised by the interest in the trial and the number of requests for participation that they received from people infected with herpes simplex virus.
"In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes," Timmler said.
AiCuris CEO Rubsamen-Schaeff said that they hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes.
Share:
上面的那条新闻, 最新的美国药厂的新药, 还是抑制药, 不是根治药。 每天一粒而已, 我认为不是根治的药, 都没什么意义。 如果有了根治的药那才让我们欣喜呢。 把这篇美国原文给大家, 大家可参考, 毕竟科学每一天都发展, 先是抑制药, 之后就会很快又治愈药啦。 大家加油啊!!!!!!!!!!!!!!! 信仰上帝, 信仰基督是个非常好的信仰, 一切都可以放下了!!